The effectiveness of packaged medicine in eradication therapy of Helicobacter pylori in Japan

Journal of Clinical Biochemistry and Nutrition

Volumn 38, Issue 2, 2006, Pages 73-76

  Kawai, Takashi ^a   Kawakami, Kohei ^a   Kataoka, Mikinori ^a   Takei, Kazuo ^a   Taira, Satoru ^b   Itoi, Takao ^b   Moriyasu, Fuminori ^b   Takagi, Yuu ^b   Aoki, Tatsuya ^b   Matsubayasiu, Jun ^a   Mukai, Kiyoshi ^a   Rimbara, Emiko ^c   Noguchi, Norihisa ^c   Sasatsu, Masanori ^c  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Eradication; Helicobacter pylori; Package set

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG CAPSULE; DRUG PACKAGING; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; TABLET FORMULATION; UREA BREATH TEST;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 33645773132     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.38.73     Document Type: Article

References (18)

1. Marshal, G.J. and Warren, J.R.: Unidentified curve bacilli in the stomach of patient with gastritis and peptic ulceration. Lancet, 16, 1131-1135, 1984.
2. Nomura, A., Stemmermann, G.N., Chyou, P.H., Kato, I., Perez-Perez, G.I., and Blaser, M.J.: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med., 325, 1132-1136, 1991.
3. Wotherspoon, A.C., Doglioni, C., de Boni, M., Spencer, J., and Isaacson, P.G.: Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet, 343, 1503, 1994.
4. Parsonnet, J., Friedman, G.D., Vanersteen, D.P., Chang, Y., Vogelman, J.H., and Orentreich N.: Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med., 325, 1127-1131, 1991.
5. Naito, Y. and Yoshikawa, T.: Carcinogenesis and chemoprevention in gastric cancer associated with Helicobacter pylori infection: role of oxidants and antioxidants. J. Clin. Biochem. Nutr., 36, 37-49, 2005.
6. Asaka, M., Sugiyama, T., Mototsugu, K., Satoh, K., Kuwayama, H., Fukuda, T., Takemoto, T., Kimura, K., Shimoyama, T., Shimizu, K., and Kobayashi, S.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter, 6, 254-261, 2001.
7. th Annual Meeting of the Japanese Society for Helicobacter Research, 2004.
8. Hokari, K., Sugiyama, T., Kato, M., Saito, M., Miyagishima, T., Kudo, M., Nishikawa, K., Ishizaka, J., Komatsu, Y., Mizushima, T., Kagaya, H., Takeda, H., and Asaka, M.: Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther., 15, 1479-1484, 2001.
9. Perri, F., Villani, M.R., Festa, V., Quitafdamo, M., and Andriulli, A.: Predictors f failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment. Pharmacol. Ther., 15, 1023-1029, 2001.
10. Kamada, T., Haruma, K., Komoto, K., Mihara, M., Chen, X., Yoshihara, M., Sumii, K., Kajiyama, G., Tahara, K., and Kawamura, Y.: Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter, 4, 204-210, 1999.
11. Kamada, T., Haruma, K., Miyoshi, E., Mihara, M., Kitadai, Y., Yoshihara, M., Sumii, K., Kajiyama, G., Tahara, K., Murai, T., Kawamura, Y., and Hattori, N.: Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment. Pharmacol. Ther., 14, 1089-1094, 2000.
12. Furuta, T., Naohito, S., Takashima, M., Xiao, F., Hanai, H., Sugimura, H., Ohashi, K., Ishuzaki, T., and Kaneko, E.: Effect of genotypic difference in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Pharmacogenet. Genomics. Clin. Pharmacol. Ther., 69, 158-168, 2001.
13. Poon, S.K., Chang, C.S., Su, J., Lai, C.H., Yang, C.C., Chen, G.H., and Wang, W.C.: Primary resistsnce to antibiotics and its clinical impact the efficacy of Helicobacter pylori lansoprazole-based triple therapy. Aliment. Pharmacol. Ther., 16, 291-216, 2002.
14. Miwa, H., Misawa, H., Yamada, T., Nagahara, A., Ohtaka, K., and Sato, N.: Clarithromycin resistance, but not CYP2C19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for the cure of H. pylori infection. Dig. Dis. Sci., 46, 2445-2450, 2001.
15. Masaoka, T., Suzuki, H., Kurabayashi, K., Kamiya, A., and Ishii, H.: Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther., 20 (Suppl), 68-73, 2004.
16. Bazzoli, F., Pozzato, P., Zagari, M., Fossi, S., Ricciardiello, L., Nicolini, G., Berretti, D., and De Luca.: Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Helicobacter, 3, 195-201, 1998.
17. Wermeille, J., Dederding, J.P., Cunningham, M., Girad, R., Baumann, G., Zeiger, N., and Godin, N.: Failure of Helicobacter pylori eradication in an ambulatory population; is poor compliance the main cause? Digestion, 59 (suppl 3), 437, 1989.
18. Asaka, M., Satoh, K., Sugano, K., Sugiyama, T., Takahashi, S., Fukuda, Y., Ota, H., Murakami, K., Kimura, K., and Shimoyama, T.: Guidelines in management of Helicobacter pylori infection in Japan. Helicobacter, 6, 177-186, 2001.